## **Prostate 2023 Case Scenario**

45-year-old male who presented with abnormal DRE, nodule/mass on LT-hand side noted with normal seminal vesicle, with elevated PSA of 14.9 taken on 5/9/2021.

5/9/2021: Prostate core bx

1. Prostate, LT base: prostatic tissue with focal high grade prostatic intraepithelial neoplasia (HGPIN),
2. Prostate, LT mid: adenocarcinoma of prostate. GS= 7(4+3), involving 60% of tissue, 1 out of 2 cores involved by tumor,
3. Prostate, LT apex: adenocarcinoma of prostate. GS= 7(4+3), involving 90% of tissue, 2 out of 2 cores involved by tumor,
4. Prostate, RT base: benign prostatic tissue,
5. Prostate, RT mid: benign prostatic tissue,
6. Prostate RT apex: small fragment suspicious for prostatic adenocarcinoma:

8 cores total taken

5/10/21: MRI pelvis: Lesion in LT mid-gland to apex peripheral zone and transitional zone with features consistent with prostate cancer. No evidence of pelvic lymphadenopathy. No EPE and No SVI identified.

5/18/21: Robotic-assisted total radical prostatectomy

**Procedure:** Radical prostatectomy

**Histologic Type: A**denocarcinoma, mixed acinar and ductal type

**Histologic Grade**

**Grade Group and Gleason Score:** Grade group 2 (Gleason score 3 + 4)

**Percentage of Pattern 4 in Gleason Score 7:** 70%

**Percentage of Pattern 5:** 0%

**Tumor Quantitation:** Carcinoma present on 14 of 20 histologic

 sections

**Extraprostatic Extension (EPE):** Not identified

**Urinary Bladder Neck Invasion:** Not identified

**Seminal Vesicle Invasion:** Not identified

**Margins:** Negative for carcinoma

**Treatment Effect on carcinoma:** No known presurgical therapy

**Lymphovascular Invasion:** Not identified

**Regional Lymph Nodes:** No nodes submitted

**Additional Pathologic Findings:** High grade prostatic intraepithelial neoplasia

|  |
| --- |
| Worksheet |
| Primary Site | **C619** |  |  | Clinical Grade | 3 |
| Histology | 8552/3 |  |  | Pathological Grade | 3 |
| RLN pos  | 98 | RLN examined | 00 | Post Therapy Grade |  |
| Laterality | 0 |
| LVI | 0 |
| Tumor size clinical | 999 |
| Tumor size path | 999 |
| Tumor size summary | 999 |
| Stage Data items |
| AJCC Stage |
| Clinical T | cT2 | Pathological T | pT2 | Post-therapy T |  |
| cT Suffix |  | pT Suffix |  | pT Suffix |  |
| Clinical N | cN0 | Pathological N | pNX | Post-therapy N |  |
| cN Suffix |  | pN Suffix |  | pN Suffix |  |
| Clinical M | cM0 | Pathological M | cM0 | Post-therapy M |  |
| Clinical Stage  | 2C | Pathological Stage | 99 | Post-therapy Stage |  |
|  |  |  |
| Summary Stage 2018  | 1-Localized |
| *EOD Primary Tumor* | 250 |
| *EOD Lymph Regional Nodes* | 000 |
| *EOD Mets* | 00 |
| *Prostate Pathologic Extension* | 300 |
| SSDI’s |
| Gleason Patterns Clinical | 43 |
| Gleason Patterns Pathological | 34 |
| Gleason Score Clinical | 07 |
| Gleason Score Pathological | 07 |
| Gleason Tertiary Pattern | X9 |
| Number of Cores Positive | 03 |
| Number of Cores Examined | 08 |
| PSA |  14.9 |
| Treatment  |
| Dx staging procedure | 02 |  |  |
| Surgery reason no rx | 0 |  |  |
| Surgical Approach at hospital | 1 |  |  |
| Surgery course | 1 |  |  |
| Surgery of primary site | 50 |  |  |
| Scope of RLN surgery | 00 |  |  |
| Surgery to other site | 00 |  |  |
| Cancer Status | 01 | 12/22/2022 Urologist note PSA <0.014 |  |